Market Overview

RBC Says New Dosing for Allergan's DARPin Could Be Positive for Regeneron's Eylea

Share:
Related REGN
5 Biotechs With Catalysts Coming This Week
Regeneron Shares Rising After Sanofi Collaboration Revealed: Good News For Shareholders?
5 Top Medical Stocks Reporting Earnings This Week (Investor's Business Daily)
Related AGN
5 Biotechs With Catalysts Coming This Week
Calls Of Note: The Street's Research Moving Stocks This Monday
5 Top Medical Stocks Reporting Earnings This Week (Investor's Business Daily)

RBC's Adnan Butt issued a note Wednesday morning suggesting the every-other-month dosing of Allergen's (NYSE: AGN) DARPin may solidify the longer-term market position for Regeneron's (NASDAQ: REGN) Eylea.

The analyst pointed out Allergan's Phase 2 study evaluating this same method "in a schedule almost identical to Eylea's."

RBC sees the study completed later this year, with the Phase 3 trial slated for completion by yearend 2014 or early 2105. This schedule of studies could indicate DARPin sales starting as soon as 2019.

RBC maintains an Outperform rating and $286 price target on shares of Regeneron Pharma.

Latest Ratings for REGN

DateFirmActionFromTo
Jul 2015JefferiesMaintainsHold
Jul 2015RBC CapitalMaintainsOutperform
Jul 2015Deutsche BankMaintainsBuy

View More Analyst Ratings for REGN
View the Latest Analyst Ratings

Posted-In: Analyst Color Analyst Ratings

 

Related Articles (REGN + AGN)

Get Benzinga's Newsletters